Differentiating agents in pediatric malignancies: All-trans-retinoic acid and arsenic in acute promyelocytic leukemia

被引：20

作者：

Calleja E.M. ^{[1
]}

Warrell R.P. ^{[2
]}

Jr ^{[2
]}

机构：

[1] Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY, 10021

[2] Genta Incorporated, Berkeley Heights, NJ, 07922

来源：

Current Oncology Reports | 2000年 / 2卷 / 6期

关键词：

Arsenic; Acute Myeloid Leukemia; Retinoic Acid; Acute Promyelocytic Leukemia; Arsenic Trioxide;

D O I：

10.1007/s11912-000-0105-x

中图分类号：

学科分类号：

摘要：

Acute promyelocytic leukemia (APL) is the most potentially curable type of acute myeloid leukemia. It is characterized by the chromosomal translocation t(15;17), which results in the fusion gene PML-RAR-alpha. The introduction of all-trans- retinoic acid (ATRA) was a major advance in treatment of this disease. This agent induces terminal differentiation of malignant myeloid cells to mature neutrophils, and its side effects are usually well tolerated in children. ATRA does not eradicate the malignant myeloid clone in APL and, eventually, resistance develops. Arsenic trioxide induces nonterminal differentiation of malignant promyelocytes and promotes apoptosis. APL patients treated with ATRA or arsenic trioxide have rapid resolution of their coagulopathy. Because both of these drugs are well tolerated in children and their synergy has been shown in animal models, the possibility of combining ATRA and arsenic trioxide in front-line therapy for children with APL is being considered.

引用

页码：519 / 523

页数：4

共 42 条

[1]

Ebb D, Weinstein H, Diagnosis and treatment of childhood acute myelogenous leukemia, Pediatr Clin North Am, 44, pp. 847-862, (1997)

[2]

Schaison GS, Acute promyelocytic leukemia in children, Pediatr Hematol Oncol, 15, pp. 203-206, (1998)

[3]

Biondi A, Rovelli A, Cantu-Rajnoldi A, Acute promyelocytic leukemia in children: experience of the Italian Pediatric Hematology and Oncology Group (AIEOP), Leukemia, 8, pp. 1264-1268, (1994)

[4]

Fenaux P, Chomienne C, Degos L, Acute promyelocytic leukemia: biology and treatment, Semin Oncol, 24, pp. 92-102, (1997)

[5]

Daly PA, Schiffer CA, Wiernik PH, Acute promyelocytic leukemia: clinical management of 15 patients, Am J Hematol, 8, pp. 347-359, (1980)

[6]

The H, Lavau C, Marchio A, The PML RAR alpha fusion in RNA generated by the t(15

[7]

17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR, Cell, 66, pp. 675-684, (1991)

[8]

Warrell RP, The H, Wang Z, Degos L, Acute promyelocytic leukemia, N Engl J Med, 329, pp. 177-189, (1993)

[9]

Biondi A, Rambaldi A, Pandolfi PP, Molecular monitoring of the myl/retinoic acid receptor-alpha fusion gene in acute polymerase chain reaction, Blood, 80, pp. 492-497, (1992)

[10]

Miller WH, Levine K, DeBlasio A, Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA, Blood, 82, pp. 1689-1694, (1993)

← 1 2 3 4 5 →